|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for YWHAG |
 Gene summary |
| Basic gene Info. | Gene symbol | YWHAG |
| Gene name | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma | |
| Synonyms | 14-3-3GAMMA|PPP1R170 | |
| Cytomap | UCSC genome browser: 7q11.23 | |
| Type of gene | protein-coding | |
| RefGenes | NM_012479.3, | |
| Description | 14-3-3 gamma14-3-3 protein gammaKCIP-1protein kinase C inhibitor protein 1protein phosphatase 1, regulatory subunit 170tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605356 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000170027 | ||
| HPRD : 05639 | ||
| Vega : OTTHUMG00000022862 | ||
| Protein | UniProt: P61981 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_YWHAG | |
| BioGPS: 7532 | ||
| Pathway | NCI Pathway Interaction Database: YWHAG | |
| KEGG: YWHAG | ||
| REACTOME: YWHAG | ||
| Pathway Commons: YWHAG | ||
| Context | iHOP: YWHAG | |
| ligand binding site mutation search in PubMed: YWHAG | ||
| UCL Cancer Institute: YWHAG | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for YWHAG |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S46 | S46C | BRCA | 1 | G174 | G174V | LUAD | 1 | R57 | R57C | OV | 1 | N51 | V52I | STAD | 1 | R57 | R57H | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for YWHAG |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | N51 | V52I | -0.81457164 | R57 | R57H | -0.75241149 | S46 | S46C | -0.71115118 | R57 | R57C | -0.5102945 | G174 | G174V | -0.24901314 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for YWHAG from PDB |
| Top |
| Differential gene expression and gene-gene network for YWHAG |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for YWHAG |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for YWHAG |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of YWHAG go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (SER,PRO,SER,LEU,PRO,ASN,ILE,THR,LEU) | 3uzd | A | N51 R57 | III | Peptide ligand (ARG,ARG,ALA,VAL,SER,GLU,LEU,ASP,ALA) | 4j6s | C | N51 R57 | III | Peptide ligand (ARG,ARG,ALA,VAL,SER,GLU,LEU,ASP,ALA) | 4j6s | D | N51 R57 G174 | III | Peptide ligand (ARG,ALA,ILE,SER,LEU,PRO) | 2b05 | A | R57 | III | Peptide ligand (ARG,ALA,ILE,SER,LEU,PRO) | 2b05 | B | R57 | III | Peptide ligand (ARG,ALA,ILE,SER,LEU,PRO) | 2b05 | C | R57 | III | Peptide ligand (ARG,ALA,ILE,SER,LEU,PRO) | 2b05 | D | R57 | III | Peptide ligand (ALA,ILE,SER,LEU,PRO) | 2b05 | E | R57 | III | Peptide ligand (ARG,ALA,ILE,SER,LEU,PRO) | 2b05 | F | R57 | III | Peptide ligand (THR,ALA,ARG,SER,LYS,VAL) | 4o46 | B | R57 | III | Peptide ligand (THR,ALA,ARG,SER,LYS,VAL) | 4o46 | C | R57 | III | Peptide ligand (THR,ALA,ARG,SER,LYS,VAL) | 4o46 | D | R57 | III | Peptide ligand (THR,ALA,ARG,SER,LYS,VAL) | 4o46 | E | R57 | III | Peptide ligand (SER,LYS) | 4o46 | F | R57 | III | Peptide ligand (ARG,ARG,ALA,VAL,SER,GLU,LEU,ASP,ALA) | 4j6s | B | R57 G174 | III | Peptide ligand (THR,ALA,ARG,SER,LYS,VAL) | 4o46 | A | R57 G174 | III | Peptide ligand (ARG,ALA,VAL,SER,GLU,LEU,ASP) | 4j6s | A | S46 R57 G174 |
| Top |
| Conservation information for LBS of YWHAG |
| Multiple alignments for P61981 in multiple species |
| LBS | AA sequence | # species | Species | E185 | SVFYYEIQNAP | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | G174 | HPIRLGLALNY | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | I222 | KDSTLIMQLLR | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | K125 | KVFYLKMKGDY | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | K50 | LSVAYKNVVGA | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | L177 | RLGLALNYSVF | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | L225 | TLIMQLLRDNL | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | L232 | RDNLTLWTSDQ | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | N178 | LGLALNYSVFY | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | N229 | QLLRDNLTLWT | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | N51 | SVAYKNVVGAR | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | R132 | KGDYYRYLAEV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | R57 | VVGARRSSWRV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | R61 | RRSSWRVISSI | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | S46 | ERNLLSVAYKN | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | V181 | ALNYSVFYYEI | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | V47 | RNLLSVAYKNV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | W233 | DNLTLWTSDQQ | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus | Y133 | GDYYRYLAEVA | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Gallus gallus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |